Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications

Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications

Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. The components of the metabolic syndrome - obesity,...

Full description

Saved in:
Bibliographic Details
Published in:Postȩpy dermatologii i alergologii Vol. 37; no. 4; pp. 468 - 474
Main Authors: Klujszo, Elzbieta H, Parcheta, Piotr, Witkowska, Anna B, Krecisz, Beata
Format: Journal Article
Language:English
Published: Poland Termedia Publishing House 01-01-2020
Subjects:
Insulin resistance
Liver diseases
Metabolic syndrome
Psoriasis
Review Paper
methotrexate
biologic agents
liver disease
psoriasis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. The components of the metabolic syndrome - obesity, lipid abnormalities, hypertension, and type 2 diabetes - significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis and insulin resistance and risk factors for metabolic syndrome should also been screened for NAFLD, and planning of the treatment options should always take into consideration the possible risks related to the liver, especially in patients with NAFLD.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1642-395X
2299-0046
DOI:10.5114/ada.2019.83983